Platinum compounds: Mechanisms of action, mechanisms of cellular resistance in human cancers, interactions with ionising radiations, application to carboplatin;Sels de platine: Mecanismes d'action cytotoxique, mecanismes de resistance de la cellule cancereuse, interactions avec les radiations ionisantes, specificite du carboplatine

Bulletin du Cancer

Volumn 87, Issue SPEC. ISS. AUG., 2000, Pages 7-15

  Rixe, O ^a  

^a Clinique Claude Bernard   (France)

Author keywords

Platinum compound

Indexed keywords

CARBOPLATIN; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; CISPLATIN; CISPLATIN DNA ADDUCT; CISPLATIN-DNA ADDUCT; GLUTATHIONE; METALLOTHIONEIN; RADIOSENSITIZING AGENT;

CANCER THERAPY; CELL DAMAGE; DNA DAMAGE; DNA REPAIR; DRUG TRANSPORT; GENE AMPLIFICATION; GENE EXPRESSION; IONIZING RADIATION; MULTIDRUG RESISTANCE; ONCOGENE; PROTEIN MODIFICATION; REVIEW; BIOSYNTHESIS; CELL CULTURE; CELL MEMBRANE; DNA ADDUCT; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL MEMBRANE; CISPLATIN; DNA ADDUCTS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; GLUTATHIONE; HUMANS; METALLOTHIONEIN; ONCOGENES; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 0033811511     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode
2. Platinum compounds: A new class of potent antitumor agents
3. High-dose cisplatin in hypertonie saline
4. Cisplatin
5. Chemotherapy of disseminated testicular cancer: A random prospective study
6. Cisplatinum and platinum analogues: Recent advances
7. Fundamental studies with cisplatin
8. Structural aspects of platinum anticancer drug interactions with DNA
9. In vivo cis-diamminedichloroplatinum(II)-DNA adduct formation and removals as measured with immunochemical techniques
10. Reevaluation of interaction of cisdiamminedichloroplatinum (II) with DNA
11. Inhibition of amino acid transport by cis-diamminedichloroplatinum (II) derivafives in L1210 murine leukemia cells
12. + adenosine triphosphatase in the accumulation of cisdiamminedichloroplatinum(II) in human ovarian carcinoma cells
13. The effect of cisplatin on renal ATPase activity in vivo and in vitro
14. Changes in calcium channel activity in membranes from cisdiamminedichloroplatinum (II)-resistant and sensitive L1210 cells
15. Mitochondrial defects in cisdiamminedichloroplatinum (II)-resistant human ovarian carcinoma cells
16. In vitro study of microtubule assembly by cis-dichlorodiammineplatinum
17. Cisdiamminedichloroplatinum (II) induces c-jun expression in human myeloid leukemia cells: Potentiel involvement of a protein kinase C-dependent signaling pathway
18. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems
19. Platinum complexes in cancer medicine
20. Stability of cisplatin, iproplatin carboplatin, and tetraplatin in commonly used intravenous solutions
21. Oxaliplatin, tetraplatin, cisplatin and carboplatin: Spectrum of activity in drug-resistant cell lines of the National Cancer Institute's Anticancer Drug Screen Panel
22. Hyperthermic potentiation of cisdiamminedichloroplatinum (II) cytotoxicity in Chinese hamster ovary cells resistant to the drug
23. Multiple mechanisms of resistance to cis-diamminedichloroplatinum (II) in murine leukemia L1210
24. Biochemical studies on resistance to cisplatinum in L1210 leukemia
25. Characterization of a human squamous carcinoma cell line resistant to cisdiamminedichloroplatinum
26. Possible mechanism for differences in sensitivity to cis-platinum in human prostate tumor cell lines
27. Altered cisplatin metabolism in cisplatin resistant 2,008 human ovarian carcinoma cells
28. Characterization of cis-platin resistant COLO 316 human ovarian carcinoma cells
29. Rapid emergence of acquired cis-diamminedichloroplatinum (II) resistance in an in vivo model of human ovarian carcinoma
30. Decreased accumulation as a mechanism of resistance to cisdiamminedichloroplatinum (II) in human non-small cell lung cancer cell lines: Relation to DNA damage and repair
31. Multiple-drag resistance in human cancer
32. Pleiotropic-resistant phenotype is a multifactorial phenomenon in human colon carcinoma lines
33. Cis-diamminedichloroplatinum (II)-resistant sublines derived from two human ovarian tumor celll lines
34. Increased DNA repair as mechanism of acquired resistance to cisdiamminedichloroplatinum (II) in human ovarian cancer cell lines
35. Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum
36. Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum (II)
37. Reversal of cisplatin resistance with amphotericin B in a non-small lung cancer cell line
38. In vivo and in vitro binding of platinum to metallothionein
39. Function of metallothionein
40. Metallothionein
41. Resistance against cis-diamminedichloroplatinum in culture cells with high content of metallothionein
42. Overexpression of metallothionein confers resistance to anticancer drugs
43. Overexpressed human metallothionein II A gene protects Chinese hamster ovary cells from killing by alkylating agents
44. Metallothioneins and cisplatin resistance
45. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells
46. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer
47. Differential effects on cell killing in metallothionein overexpressing CHO mutant cell lines
48. Glutathione metabolism and its selective modification
49. Glutathione
50. Gluthatione and related γ-glutamyl compounds biosynthesis and utilisation
51. Diverse mechanisms and methods of overcoming cis-platinum resistance in L1210 leukemia cells
52. Characterization of a cisdiamminedichloroplatinum (II)-resistant human carcinoma cell line and its use in evaluation of platinum analogs
53. Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and drug sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion
54. Differential expression of collateral sensitivity or resistance to cisplatin in human bladder carcinome cell lines pre-exposed in vitro to either irradiation or cisplatin
55. Resistance to alkylating agents and cisplatin : Insights from ovarian carcinoma model systems
56. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion
57. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis
58. Cellular pharmacology of cisplatin : Perspectives on mechanisms of acquired resistance
59. Quantitative estimation of cisplatin-induced DNA interstrand cross-links and their repair in mammalian cells : Relationship to toxicity
60. Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells, treated with cis-diamminedichloroplatinum (II)
61. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair deficient human fibroblasts
62. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum (II)
63. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy
64. Gene specific formation and repair of cisplatin intrastrand adducts and interstrands cross links in Chinese hamster ovary cells
65. DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum (II). Host cell reactivation of damaged plasmid DNA
66. Effect of the antitumor drug cis-diamminedichloroplatinum (II) and related complexes on eukaryotic DNA replication
67. Repair synthesis by human cell extracts in DNA damaged by cis-and trans-diamminedichloroplatinum (II)
68. Quantitation of cis-diamminedichloroplatinum (II)-DNA intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy
69. Cisplatin resistant cells express increased levels of a factor that recognizes damaged DNA
70. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin
71. Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA
72. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer
73. Modulation of cisplatin cytotoxicity by inhibition of DNA repair in a cisplatin resistant human ovarian cancer cell line
74. Expression of the DNA repair gene ERCC-1 relates to cisplatin drug resistance in human ovarian cancer cells
75. Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10
76. Elevated expression of thymidylate synthetase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells
77. Multienzyme complex for metabolic channeling in mammalian DNA replication
78. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin
79. Cisplatin resistance in human cancers
80. Modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacological alteration of microtubule function
81. Alterations in microtubule structure and function are associated with the cisplatin-resistant phenotype in a human ovarian carcinoma cell lines
82. Cisplatin resistance is multifactorial and includes changes in cytoskeletal distribution and dynamics
83. Experimental model systems of ovarian cancer: Applications to the design and evaluation of new treatment approaches
84. Development of a nucleotide precursor incorporation assay for testing drug sensitivity of human rumors
85. In vitro modulation of cisplatin resistance by amphotericin B and derivatives in ovarian and epidermoid cisplatin resistant cancer cell lines
86. Combination radiotherapy and chemotherapy for p388 lymphocytic leukemia in vivo
87. Studies on cisdichlorodiammineplatinum (II) as a radiosensitizer
88. Effect of on cis-dichlorodiammineplatinum (II) and X rays on mammalian cell survival
89. Interactions entre le carboplatine, le cisplatine et les rayonnements ionisants dans une lignee cellulaire humaine de cancer ovarien